Yahoo Finance

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

CARLSBAD, Calif., August 21, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) ...
Benzinga.com

Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile

Friday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE). Donidalorsen had a ...
The New England Journal of Medicine

Efficacy and Safety of Donidalorsen for Hereditary Angioedema

Hereditary angioedema is a rare disorder characterized by episodic, potentially life-threatening swelling caused by kallikrein–kinin dysregulation. Long-term prophylaxis can stabilize this system.
Business Wire

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as ...
Business Wire

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

HAE is a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling (angioedema) in various parts of the body, including the hands, feet, genitals, ...
Benzinga.com

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach

Monday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, ...
Healio

Donidalorsen may reduce hereditary angioedema attack rates

Please provide your email address to receive an email when new articles are posted on . Donidalorsen was effective in improving disease control and quality of life measures in patients with hereditary ...
Nasdaq

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema

CARLSBAD, Calif., May 31, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients ...
Healio

FDA approves donidalorsen for hereditary angioedema attack prevention

Please provide your email address to receive an email when new articles are posted on . The FDA based donidalorsen’s approval on phase 3 OASIS-HAE trial results. This marks the first RNA-targeted ...
Hosted on MSN

FDA approves Ionis’ donidalorsen for HAE attack prevention

The US Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals’ RNA-targeted prophylactic treatment, Dawnzera (donidalorsen), for use in preventing hereditary angioedema (HAE) attacks in ...
The Globe and Mail

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with hereditary angioedema (HAE) were ...